A Phase 4 interventional study of Nivolumab Injectable Product and Nivolumab in Renal Cell Carcinoma and Kidney Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 4, Interventional, and Treatment
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
1,992 studies on the registry are indexed under Carcinoma, Renal Cell; 387 are open to participants now.
This study's planned enrollment of 40 is close to the median of 42 across 1,501 interventional studies indexed under Carcinoma, Renal Cell.
Browse Carcinoma, Renal Cell studies →Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,957 studies on the registry; 323 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 68 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Patients:
A patient cannot be considered eligible for this study unless ALL of the following conditions are met.
Patient has at least 6 doses of planned treatment left as standard of care that can be given on protocol (either NIVO or PEMBRO)
Providers (Medical Oncologists):
Participants will be randomized to receive IV nivolumab/NIVO or pembrolizumab/PEMBRO
Drug: Nivolumab · Drug: Pembrolizumab
Participants will be randomized to receive subcutaneous nivolumab/NIVO or pembrolizumab/PEMBRO
Drug: Nivolumab Injectable Product · Drug: Pembrolizumab injection
Participants will be randomized to receive nivolumab subcutaneously
Participants will be randomized to receive Nivolumab intravenously
Participants will be randomized to receive Pembrolizumab subcutaneously
Participants will be randomized to receive Pembrolizumab intravenously
Part I: Participants preference between intravenous/IV vs subcutaneous/SC immune checkpoint inhibitor (NIVO and PEMBRO) for Renal Cell Carcinoma.
The primary outcome is participants preference between the two formulations.
Time frame: 1 year
Part 2: Participant Preference between Standard of Care Delivery vs Labs at Home +Telehealth Visit
The primary outcome is participant preference between the two delivery models.
Time frame: 1 year
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Pembrolizumab
Memorial Sloan Kettering Cancer Center →